Jean-Guy Delcros

Title: Jean-Guy Delcros: Innovator in Cancer Treatment

Introduction

Jean-Guy Delcros is a notable inventor based in Lyons, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of antibodies. With a total of 2 patents, Delcros is recognized for his work in the medical and pharmaceutical industries.

Latest Patents

Delcros's latest patents focus on the development of an anti-netrin-1 antibody. This application discloses a method of treating cancer by utilizing a linear or substantially linear epitope on netrin-1. This epitope corresponds to the specific binding region of netrin-1 to receptors, particularly of the UNC5 class, such as UNC5B and UNC5A. The invention aims to prevent the interaction between netrin-1 and its receptors, which is crucial for inducing apoptosis or cell death in tumor cells that express or overexpress netrin-1. The application also includes a murine monoclonal antibody directed against this epitope and various humanized forms thereof.

Career Highlights

Jean-Guy Delcros is currently associated with Netris Pharma, where he continues to advance his research in cancer therapies. His work has been instrumental in developing innovative solutions that target specific cancer pathways, thereby improving treatment outcomes for patients.

Collaborations

Delcros collaborates with fellow researcher Yann Dean, contributing to the advancement of their shared goals in cancer research and antibody development.

Conclusion

Jean-Guy Delcros is a prominent figure in the field of cancer treatment, with a focus on innovative antibody therapies. His contributions through patents and collaborations highlight his commitment to improving patient care and advancing medical science.